Drug Trial Radar · NCT03222583
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
Last checked: Nov 20, 2026Latest source record: Dec 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
546
Actual
Start
Oct 4, 2017
Primary completion
Oct 18, 2018
Study completion Feb 15, 2019
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) with or without ribavirin (RBV), OR sofosbuvir with RBV with or without IFN.
Conditions
- Hepatitis C Virus (HCV)
Interventions
PlaceboDrug
Matching placebo tablet for oral administration
Glecaprevir/PibrentasvirDrug
Coformulated tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)Time frame: 12 weeks after the last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen.
- Percentage of HCV GT1-Infected Participants in Arm A Who Achieved SVR12Time frame: 12 weeks after last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen
- Percentage of HCV GT2-Infected Participants in Arm A Who Achieved SVR12Time frame: 12 weeks after the last dose of study drug, Week 20 or Week 28 depending on the treatment regimen.
Locations
48 sites in 3 countries. Site status is shown where the registry gives one.
Beijing Di Tan Hospital, Capital Medical University /ID# 156847
Beijing, China
1st Hospital of Peking Uni /ID# 156845
Beijing, China
302 Military Hospital Of China /ID# 156841
Beijing, China
Beijing Friendship Hospital /ID# 156840
Beijing, China
Beijing Youan Hosp, Cap Med Un /ID# 163430
Beijing, China
1st Affiliated Hosp 3rd Milita /ID# 156831
Chongqing, China
Dalian Sixth Peoples Hospital /ID# 163433
Dalian, China
Mengchao Hepatobiliary Hospita /ID# 156902
Fuzhou, China
Hainan General Hospital /ID# 156839
Haikou, Hainan, China
Jinan Infectious Diseases Hosp /ID# 156886
Jinan, Shandong, China
Chinese People's Liberation Army 81 Hospital /ID# 156862
Nanjing, China
Shengjing Hospital of China Medical University /ID# 156824
Shenyang, China
Tianjin Third Central Hospital /ID# 156816
Tianjin, China
1st Aff Hosp Xinjiang Med Uni /ID# 156887
Ürümqi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 156884
Wuhan, China
Tongji Hosp Tongji Med College /ID# 156885
Wuhan, China
Fourth Military Medical University Tangdu Hospital, PLA /ID# 156765
Xi'an, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University /ID# 163432
Xi'an, China
Henan Provincial Peoples Hosp /ID# 157197
Zhengzhou, Henan, China
Peking University Peoples Hospit /ID# 156846
Beijing, Beijing Municipality, China
Guangzhou Eighth People's Hosp /ID# 156859
Guangzhou, Guangdong, China
Guangdong General Hospital /ID# 156822
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 156860
Guangzhou, Guangdong, China
The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156900
Guangzhou, Guangdong, China
Xiangya Hospital Central South University /ID# 156901
Changsha, Hunan, China
The Second Hospital of Nanjing /ID# 156863
Nanjing, Jiangsu, China
Jiangsu Province People's Hospital /ID# 156861
Nanjing, Jiangsu, China
The First Hosp of Jilin Univ /ID# 156820
Changchun, Jilin, China
The Sixth People's Hospital of Shenyang /ID# 156849
Shenyang, Liaoning, China
Shanghai Changzheng Hospital /ID# 158072
Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong /ID# 157336
Shanghai, Shanghai Municipality, China
Huashan Hospital of Fudan University /ID# 156904
Shanghai, Shanghai Municipality, China
Shanghai Public Health Cli Ctr /ID# 156832
Shanghai, Shanghai Municipality, China
West China Hospital /ID# 156830
Chengdu, Sichuan, China
National University Hospital ( /ID# 163272
Singapore, Singapore
Singapore General Hospital /ID# 163271
Singapore, Singapore
Changi General Hospital /ID# 163270
Singapore, Singapore
Seoul National University Hospital /ID# 163348
Seoul, South Korea
Asan Medical Center /ID# 163336
Seoul, South Korea
Pusan National University Hosp /ID# 163371
Busan, Busan Gwang Yeogsi, South Korea
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.